Navigation Links
Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
Date:4/17/2013

em disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding that it may obtain orphan drug designation for OMS721; the potential indications that OMS721 may treat; the potential advantages of OMS721 over current treatments; when OMS721 will begin clinical development; that it will apply for orphan drug designation for OMS721 in Europe; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
2. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
3. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
4. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
5. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
6. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
7. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
11. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BURLINGTON, Mass., Dec. 12, 2011 /PRNewswire-iReach/ -- ... Financial. Tom joined Ametros as executive vice president in ... in the workers, compensation managed care industry. He served ... Medical, vice president of national occupational health for Kaiser ...
... Ontario, Dec. 12, 2011  Valeant Pharmaceuticals International, Inc. ... at a special meeting of shareholders of Afexa ... today in Calgary, Alberta, the shareholders of Afexa ... subsidiary, 1625907 Alberta Ltd. (the " Offeror ") ...
Cached Medicine Technology:Ametros Financial Names Thomas Ash as CEO 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 3
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... the arm by way of a novel research conducted by ... endowed with the potential to inhibit the growth of blood ... may throw open a plethora of options to fight cancer ... University, previous research has indicated the benefits of aspirin in ...
... down for decades, ever since studies showed a strong link ... experts have suggested that some people should aim even lower, ... called low-density lipoprotein for some high-risk people — even if ... there. ,Not so fast, says a team of researchers ...
... Among patients with schizophrenia whose medication is changed ... antipsychotic drugs do not appear to offer significant ... a report in the October issue of Archives ... ,The findings run contrary to the ...
... less than 2,000 grams (about 4.5 pounds) at birth ... the average teenager to have physical and mental difficulties, ... Archives of Pediatrics & Adolescent Medicine, one of the ... increase the risk for major disabilities such as cerebral ...
... unexplored regions of the human genome are thousands of ... growth of breast cancer is driven by estrogen, new ... ,In the October issue of Nature Genetics, the investigators ... panels" -- stretches of DNA that turn genes on ...
... has apologized to a woman who had a miscarriage in ... to go through the process.// ,On Tuesday Health region ... are sorry that this situation occurred and we empathize with ... the circumstances of this case, as we do with all ...
Cached Medicine News:Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 2Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 3Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 4Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Low Birth Weight Babies May Have Mental & Physical Problems 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: